Biopharmaceuticals
Haikou has accelerated the implementation of the “Eight Action Plan” to establish the “National Biopharmaceutical Industry Platform of Haikou Medicine Valley” and cultivate a “100-Billion-Level Biopharmaceutical Industry Cluster”. The Shanghai Zhangjiang Group - Haikou National Hi-tech Industrial Development Zone two-way incubator was inaugurated, marking the start of strategic cooperation on an inter-provincial “demonstration park for enclave economic cooperation”. The Hainan National Technology Transfer Center has been officially put in operation, completing the production of the first batch of “orphan drugs” for the treatment of rare diseases. Bloomage Biotechnology commenced operating Hainan’s first GMP cell culture medium production line. Poly Pharm and Huluwa Pharmaceutical have been recognized as two of “China’s Most Investable Pharmaceutical Enterprises”. Haikou has deepened “Lecheng R&D + Haikou Production” collaboration and formed efficient coordination of “front-end research + middle-end development + back-end application” across the entire biomedical industry chain, attracting a swath of high-quality domestic and foreign enterprises such as Haiping Group, Qilu, Simcere Pharmaceutical, and Viatris.
Haiping Group - International Medical Device Park in Haikou National Hi-tech Industrial Development Zone
Located in the Haikou National Hi-tech Industrial Development Zone's Mei'an Ecological Technology New City, the International Medical Device Park project covers a total planned area of 230 mu (1 mu = 666.67 ㎡), with a building area of 390,000 ㎡. It plans to attract more than 300 medical device enterprises and related supporting enterprises, achieve an annual output value of over 10 billion yuan, and become a representative professional medical device park in Haikou characterized by high technology, high output value, and high tax revenue. The project is the fastest-developing park within Haiping Group and enjoys benefits including “corporate secretary” services, streamlined approval procedures, and immediate construction upon land acquisition. In October 2023, Phase I of the project witnessed the issuance of property certificates for 16 factory buildings, and 80% of the project’s constructed areas are already ready to welcome investment.
Minyin International Holdings Group - R&D and Manufacturing Base for Scientific and Intelligent Medical Devices
Minyin International Holdings Group, a subsidiary of the globally renowned bowling equipment manufacturer, Xima Bowling Equipment Co., Ltd., is investing in building a research and manufacturing base for scientific and intelligent medical devices in the Haikou National High-Tech Industrial Development Zone. The project covers an area of 20 mu (1 mu = 666.67 ㎡), with a total investment of 300 million yuan. Leveraging the Hainan Free Trade Port's favorable conditions, Haikou's advantageous location, and policies such as the 30% Valued-Added Processing Import Duty Exemption Policy, 15% Corporate Income Tax Rate for Enterprises in Encouraged Industries, and 15% Individual Income Tax Rate for High-caliber, Urgently Needed Talents, the project positions itself to be a R&D and production base for products related to pharmaceuticals, medical devices, intelligent robots, and IoT smart manufacturing.
Industrial Policies
Key Hainan Free Trade Port Policies
Provincial and Municipal Support Policies
